此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

SUPER Study; SUPERvised Exercise or Angioplasty for Intermittent Claudication Due to an Iliac Artery Obstruction. (SUPER)

2018年2月12日 更新者:M.J.W. Koelemaij

SUPERvised Exercise Therapy (SET) or Immediate Percutaneous Transluminal Angioplasty (PTA) for Intermittent Claudication (IC) in Patients With an Iliac Artery Obstruction: A Randomized Controlled Trial. SUPER Study

The purpose of our study is to compare the clinical effectiveness and cost-effectiveness of two treatment strategies of Intermittent Claudication (IC) due to an iliac artery obstruction: to start with SUPERvised Exercise Therapy (SET) and deferred Percutaneous Transluminal Angioplasty (PTA) in case of SET failure, or immediate PTA.

It is our hypothesis that PTA as first line treatment is more effective than SET as first line treatment with regard to maximum walking distance, quality of life and costs after one year.

研究概览

详细说明

Intermittent claudication (IC) is a manifestation of cardiovascular disease, reflected by a threefold increased risk in these patients of developing serious cardiovascular events. Treatment of patients with IC is aimed at secondary prevention of cardiovascular events by control of risk factors for atherosclerotic disease, and to improve walking distance and subsequently quality of life. Supervised Exercise Therapy (SET) and Percutaneous Transluminal Angioplasty (PTA) can effectively improve pain free walking distance, but the optimal choice of treatment, specifically in patients with an iliac artery stenosis or occlusion is unclear. PTA is attractive as initial therapy since PTA of the iliac arteries has an immediate effect and it is durable. There is a lack of evidence from randomized controlled trials (RCT) to define the optimal treatment strategy for patients with IC due to iliac artery lesions; first line treatment with SET and PTA in case of failure, or immediate iliac artery PTA.

Purpose:

To define the optimal treatment strategy of IC due to an iliac artery obstruction: To start with SET and deferred PTA in case of SET failure, or immediate PTA.

Design:

Multicenter randomized controlled trial.

Patients:

400 patients with IC due to an iliac artery stenosis or occlusion.

Interventions:

SET and PTA.

Outcomes:

Primary outcomes are quality of life (Qol) recorded with the disease specific VascuQol instrument and maximum walking distance on a standardized treadmill test with a speed of 3.2 km/h at 10% incline after 1 year.

Secondary outcomes are pain-free walking distance, generic Qol, functional status, complications, number of treatment failures and costs. Economic evaluation comprises a cost-effectiveness and cost-utility analysis from a societal perspective, with the costs per patient able to walk maximal, respectively the costs per Quality Adjusted Life-Year (QALY) as outcome measures.

研究类型

介入性

注册 (实际的)

240

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Almere、荷兰、1315 RA
        • Flevoziekenhuis
      • Amsterdam、荷兰、1105 AZ
        • Academic Medical Center
      • Amsterdam、荷兰、1091 AC
        • Onze Lieve Vrouwe Gasthuis
      • Amsterdam、荷兰、1081 HV
        • VU Medical Center
      • Amsterdam、荷兰、1061 AE
        • Sint Lucas Andreas Ziekenhuis
      • Apeldoorn、荷兰、7334 DZ
        • Gelre Ziekenhuizen
      • Arnhem、荷兰、6815 AD
        • Ziekenhuis Rijnstate
      • Beverwijk、荷兰、1942 LE
        • Rode Kruis Ziekenhuis
      • Deventer、荷兰、7416 SE
        • Deventer Ziekenhuis
      • Haarlem、荷兰、2035 RC
        • Kennemer Gasthuis
      • Hilversum、荷兰、1213 XZ
        • Tergooiziekenhuizen
      • Hoofddorp、荷兰、2134 TM
        • Spaarne Ziekenhuis
      • Nieuwegein、荷兰、3435 CM
        • St Antonius Ziekenhuis
      • Nijmegen、荷兰、6525 GA
        • UMC St. Radboud
      • Purmerend、荷兰、1441 RN
        • Waterland Ziekenhuis

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Age 18 years or older;
  2. Disabling claudication as defined by surgeon based on patient's history;
  3. Ankle/Brachial Index (ABI) < 0.9 or drop in ABI > 0.15 after exercise test;
  4. Hemodynamic stenosis of the common or external iliac artery on Color Duplex Scanning (CDS) (PSV ratio ≥ 2.5 or EDV ≥ 0.6 m/s) or on Magnetic Resonance Angiography (MRA) or Computed Tomography Angiography (CTA)(> 50% stenosis) or occlusion of the common or external iliac artery on CDS (PSV 0 m/s) or on MRA or CTA;
  5. Iliac artery lesion and a concomitant stenosis in the superficial femoral artery defined as stenosis > 50% by CDS (PSV ratio ≥ 2.5 or EDV ≥ 0.6 m/s) or on MRA or CTA, or occlusion on CDS (PSV 0 m/s) or MRA or CTA;
  6. Lesion classified A, B or C according to the TASC (TransAtlantic Inter-Society Consensus) classification of aortoiliac lesions;
  7. Patient is able to walk at least 2 minutes on a treadmill at 3.2 km/h and 10% incline;
  8. The Maximum Walking Distance on a treadmill < 300 meters.

Exclusion Criteria:

  1. Life expectancy < 3 months;
  2. Patient is unable to complete self-reported questionnaires (insufficiently reading or speaking the Dutch language, cognitive disorders, etc);
  3. Patient is unable to give informed consent;
  4. A documented contrast allergy;
  5. Pregnancy;
  6. Contra-indication for anticoagulant therapy;
  7. Duration of current complaints < 3 months;
  8. Occlusion of the common femoral artery at the affected side;
  9. Patient participates in another study;
  10. Heart failure or Angina Pectoris NYHA III or IV. (NYHA III: Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes fatigue, palpitation, or dyspnea; NYHA IV: Unable to carry out any physical activity without discomfort. Symptoms of cardiac insufficiency at rest. If any physical activity is undertaken, discomfort is increased);
  11. Patient previously received Supervised Exercise Therapy (SET) according to KNGF (Dutch Society for Physiotherapists) guidelines;
  12. Renal insufficiency (serum creatinin > 150 micromol/l).

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
有源比较器:Intervention group: Angioplasty
Angioplasty with or without stent of the iliac artery
The Percutaneous Transluminal Angioplasty (PTA) procedure will be performed by an experienced interventional radiologist using a conventional guide wire and balloon catheter technique. A stent will be placed in cases in which the residual mean pressure gradient is greater than 10 mmHg across the treated site or when more than 30% stenosis after the procedure is detected. All PTA patients are encouraged perform at least three walking sessions every day.
其他名称:
  • 血管内治疗
有源比较器:Control: Supervised Exercise Therapy
Supervised exercise therapy by a physiotherapist
Supervised Exercise Therapy (SET) will take place in the hospital or community based according to the guidelines of the Dutch Society for Physiotherapists. The duration of the treatment will be at least 6 months and with a frequency of 2 times a week for at least 60 minutes and an intensity near maximum pain barrier (defined as pain of which it is not possible to be distracted). The frequency of the training will decrease after 3 months and the patients will receive homework, make a plan and keep a log of their exercise activities. Furthermore the program consists of walking pattern improvement and enhancement of endurance and strength. All SET patients are encouraged to perform at least three walking sessions every day on their own.
其他名称:
  • 保守治疗

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Disease specific Quality of Life
大体时间:12 months

Disease specific Quality of life (Qol) recorded with the disease specific VascuQol instrument 1 year after intervention.

The VascuQol will be completed at baseline and 1,6,12 months follow-up.

12 months
Maximum Walking Distance
大体时间:12 months

Maximum walking distance on a standardized treadmill test with a speed of 3.2 km/h at 10% incline measured 1 year after intervention.

The maximum walking distance will be assessed at baseline and 1,6,12 months follow-up.

12 months

次要结果测量

结果测量
措施说明
大体时间
Painfree Walking Distance
大体时间:12 months

Painfree walking distance on a standardized treadmill test with a speed of 3.2 km/h at 10% incline 1 year after intervention.

The painfree walking distance will be assessed at baseline and 1,6,12 months follow-up.

12 months
Functional Status
大体时间:12 months

Functional status assessed by the AMC Linear Disability Score (ALDS) 1 year after intervention.

The ALDS will be completed at baseline and 1,6,12 months follow-up.

12 months
Generic Quality of Life
大体时间:12 months

Generic quality of life (Qol) recorded with the Short Form 36 (SF-36) and EQ-5D (former EuroQoL).

The SF-36 will be completed at baseline and 1,6,12 months follow-up. The EQ-5D will be completed at baseline, 1 week and 1,6,12 months follow-up.

12 months
Complications
大体时间:During 12 months
Complications related to both interventions during 12 months.
During 12 months
Treatment failures
大体时间:During 12 months
A treatment failure is defined as crossover to the other treatment arm.
During 12 months
Costs
大体时间:During 12 months
Costs during 1 year.
During 12 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Mark JW Koelemay, M.D., Ph.D、Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
  • 首席研究员:Jim A Reekers, M.D., Ph.D.、Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
  • 首席研究员:Dink A Legemate, M.D.,Ph.D.、Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
  • 研究主任:Shandra Bipat, Ph.D.、Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

有用的网址

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2010年11月1日

初级完成 (实际的)

2016年5月1日

研究完成 (实际的)

2016年5月1日

研究注册日期

首次提交

2011年6月28日

首先提交符合 QC 标准的

2011年6月29日

首次发布 (估计)

2011年6月30日

研究记录更新

最后更新发布 (实际的)

2018年2月13日

上次提交的符合 QC 标准的更新

2018年2月12日

最后验证

2018年2月1日

更多信息

与本研究相关的术语

其他研究编号

  • 171102025;ZonMw
  • 09/285;METC AMC (其他标识符:Protocol number; IRB AMC Amsterdam)

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅